| Jahnavi Jaladanki, | |
|
22 S Greene St, Baltimore, MD 21201-1544 | |
| (410) 328-8667 | |
| Not Available |
| Full Name | Jahnavi Jaladanki |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 7 Years |
| Location | 22 S Greene St, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033635537 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 112276 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Medstar Harbor Hospital | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medstar Medical Group Anesthesiology Llc | 1052678034 | 456 |
| Lifebridge Anesthesia Associates Llc | 2062514888 | 95 |
| Johns Hopkins University | 8921903147 | 2692 |
News Archive
ValueOptions, the nation's largest independent behavioral health and wellness company, and LifeWIRE announced today a joint teaming agreement to create a mobile monitoring, intervention and counseling program.
The moment a bacterial pathogen makes contact with its host, its goal is simple: to infect.
DynaVox, the leading provider of speech generating devices and symbol-adapted special education software used to assist individuals in overcoming speech, language and learning challenges, today announced the release of two new additions to the Vmax™ line of communication devices, the Vmax+ High Performance and the Vmax+ Battery Efficiency.
Taiho Pharmaceutical Co., Ltd. announced on May 31 that a global Phase III clinical trial (RECOURSE) for the novel combination antimetabolite TAS-102 will start in June this year.
The anti-cancer medicine venetoclax could improve the current therapy for estrogen receptor-positive breast cancer - the most common form of breast cancer in Australia - according to preclinical studies led by Walter and Eliza Hall Institute researchers.
› Verified 5 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922008549 PECOS PAC ID: 8921903147 Enrollment ID: O20031215000719 |
News Archive
ValueOptions, the nation's largest independent behavioral health and wellness company, and LifeWIRE announced today a joint teaming agreement to create a mobile monitoring, intervention and counseling program.
The moment a bacterial pathogen makes contact with its host, its goal is simple: to infect.
DynaVox, the leading provider of speech generating devices and symbol-adapted special education software used to assist individuals in overcoming speech, language and learning challenges, today announced the release of two new additions to the Vmax™ line of communication devices, the Vmax+ High Performance and the Vmax+ Battery Efficiency.
Taiho Pharmaceutical Co., Ltd. announced on May 31 that a global Phase III clinical trial (RECOURSE) for the novel combination antimetabolite TAS-102 will start in June this year.
The anti-cancer medicine venetoclax could improve the current therapy for estrogen receptor-positive breast cancer - the most common form of breast cancer in Australia - according to preclinical studies led by Walter and Eliza Hall Institute researchers.
› Verified 5 days ago
| Entity Name | North American Partners In Anesthesia Maryland Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093707879 PECOS PAC ID: 1850283144 Enrollment ID: O20040330000405 |
News Archive
ValueOptions, the nation's largest independent behavioral health and wellness company, and LifeWIRE announced today a joint teaming agreement to create a mobile monitoring, intervention and counseling program.
The moment a bacterial pathogen makes contact with its host, its goal is simple: to infect.
DynaVox, the leading provider of speech generating devices and symbol-adapted special education software used to assist individuals in overcoming speech, language and learning challenges, today announced the release of two new additions to the Vmax™ line of communication devices, the Vmax+ High Performance and the Vmax+ Battery Efficiency.
Taiho Pharmaceutical Co., Ltd. announced on May 31 that a global Phase III clinical trial (RECOURSE) for the novel combination antimetabolite TAS-102 will start in June this year.
The anti-cancer medicine venetoclax could improve the current therapy for estrogen receptor-positive breast cancer - the most common form of breast cancer in Australia - according to preclinical studies led by Walter and Eliza Hall Institute researchers.
› Verified 5 days ago
| Entity Name | University Of Maryland Medical System Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508807355 PECOS PAC ID: 7113914771 Enrollment ID: O20040427000918 |
News Archive
ValueOptions, the nation's largest independent behavioral health and wellness company, and LifeWIRE announced today a joint teaming agreement to create a mobile monitoring, intervention and counseling program.
The moment a bacterial pathogen makes contact with its host, its goal is simple: to infect.
DynaVox, the leading provider of speech generating devices and symbol-adapted special education software used to assist individuals in overcoming speech, language and learning challenges, today announced the release of two new additions to the Vmax™ line of communication devices, the Vmax+ High Performance and the Vmax+ Battery Efficiency.
Taiho Pharmaceutical Co., Ltd. announced on May 31 that a global Phase III clinical trial (RECOURSE) for the novel combination antimetabolite TAS-102 will start in June this year.
The anti-cancer medicine venetoclax could improve the current therapy for estrogen receptor-positive breast cancer - the most common form of breast cancer in Australia - according to preclinical studies led by Walter and Eliza Hall Institute researchers.
› Verified 5 days ago
| Entity Name | First Colonies Anesthesia Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740218767 PECOS PAC ID: 8426039744 Enrollment ID: O20040525000119 |
News Archive
ValueOptions, the nation's largest independent behavioral health and wellness company, and LifeWIRE announced today a joint teaming agreement to create a mobile monitoring, intervention and counseling program.
The moment a bacterial pathogen makes contact with its host, its goal is simple: to infect.
DynaVox, the leading provider of speech generating devices and symbol-adapted special education software used to assist individuals in overcoming speech, language and learning challenges, today announced the release of two new additions to the Vmax™ line of communication devices, the Vmax+ High Performance and the Vmax+ Battery Efficiency.
Taiho Pharmaceutical Co., Ltd. announced on May 31 that a global Phase III clinical trial (RECOURSE) for the novel combination antimetabolite TAS-102 will start in June this year.
The anti-cancer medicine venetoclax could improve the current therapy for estrogen receptor-positive breast cancer - the most common form of breast cancer in Australia - according to preclinical studies led by Walter and Eliza Hall Institute researchers.
› Verified 5 days ago
| Entity Name | Bestgate Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568889327 PECOS PAC ID: 9739309766 Enrollment ID: O20140925001213 |
News Archive
ValueOptions, the nation's largest independent behavioral health and wellness company, and LifeWIRE announced today a joint teaming agreement to create a mobile monitoring, intervention and counseling program.
The moment a bacterial pathogen makes contact with its host, its goal is simple: to infect.
DynaVox, the leading provider of speech generating devices and symbol-adapted special education software used to assist individuals in overcoming speech, language and learning challenges, today announced the release of two new additions to the Vmax™ line of communication devices, the Vmax+ High Performance and the Vmax+ Battery Efficiency.
Taiho Pharmaceutical Co., Ltd. announced on May 31 that a global Phase III clinical trial (RECOURSE) for the novel combination antimetabolite TAS-102 will start in June this year.
The anti-cancer medicine venetoclax could improve the current therapy for estrogen receptor-positive breast cancer - the most common form of breast cancer in Australia - according to preclinical studies led by Walter and Eliza Hall Institute researchers.
› Verified 5 days ago
| Entity Name | Maryland Endoscopy Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366818411 PECOS PAC ID: 6002117900 Enrollment ID: O20151218000689 |
News Archive
ValueOptions, the nation's largest independent behavioral health and wellness company, and LifeWIRE announced today a joint teaming agreement to create a mobile monitoring, intervention and counseling program.
The moment a bacterial pathogen makes contact with its host, its goal is simple: to infect.
DynaVox, the leading provider of speech generating devices and symbol-adapted special education software used to assist individuals in overcoming speech, language and learning challenges, today announced the release of two new additions to the Vmax™ line of communication devices, the Vmax+ High Performance and the Vmax+ Battery Efficiency.
Taiho Pharmaceutical Co., Ltd. announced on May 31 that a global Phase III clinical trial (RECOURSE) for the novel combination antimetabolite TAS-102 will start in June this year.
The anti-cancer medicine venetoclax could improve the current therapy for estrogen receptor-positive breast cancer - the most common form of breast cancer in Australia - according to preclinical studies led by Walter and Eliza Hall Institute researchers.
› Verified 5 days ago
| Entity Name | Medstar Medical Group Anesthesiology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528578333 PECOS PAC ID: 1052678034 Enrollment ID: O20171207001966 |
News Archive
ValueOptions, the nation's largest independent behavioral health and wellness company, and LifeWIRE announced today a joint teaming agreement to create a mobile monitoring, intervention and counseling program.
The moment a bacterial pathogen makes contact with its host, its goal is simple: to infect.
DynaVox, the leading provider of speech generating devices and symbol-adapted special education software used to assist individuals in overcoming speech, language and learning challenges, today announced the release of two new additions to the Vmax™ line of communication devices, the Vmax+ High Performance and the Vmax+ Battery Efficiency.
Taiho Pharmaceutical Co., Ltd. announced on May 31 that a global Phase III clinical trial (RECOURSE) for the novel combination antimetabolite TAS-102 will start in June this year.
The anti-cancer medicine venetoclax could improve the current therapy for estrogen receptor-positive breast cancer - the most common form of breast cancer in Australia - according to preclinical studies led by Walter and Eliza Hall Institute researchers.
› Verified 5 days ago
| Entity Name | Lifebridge Anesthesia Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003992868 PECOS PAC ID: 2062514888 Enrollment ID: O20230627000605 |
News Archive
ValueOptions, the nation's largest independent behavioral health and wellness company, and LifeWIRE announced today a joint teaming agreement to create a mobile monitoring, intervention and counseling program.
The moment a bacterial pathogen makes contact with its host, its goal is simple: to infect.
DynaVox, the leading provider of speech generating devices and symbol-adapted special education software used to assist individuals in overcoming speech, language and learning challenges, today announced the release of two new additions to the Vmax™ line of communication devices, the Vmax+ High Performance and the Vmax+ Battery Efficiency.
Taiho Pharmaceutical Co., Ltd. announced on May 31 that a global Phase III clinical trial (RECOURSE) for the novel combination antimetabolite TAS-102 will start in June this year.
The anti-cancer medicine venetoclax could improve the current therapy for estrogen receptor-positive breast cancer - the most common form of breast cancer in Australia - according to preclinical studies led by Walter and Eliza Hall Institute researchers.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jahnavi Jaladanki, 202 Scott St, Baltimore, MD 21230-2108 Ph: () - | Jahnavi Jaladanki, 22 S Greene St, Baltimore, MD 21201-1544 Ph: (410) 328-8667 |
News Archive
ValueOptions, the nation's largest independent behavioral health and wellness company, and LifeWIRE announced today a joint teaming agreement to create a mobile monitoring, intervention and counseling program.
The moment a bacterial pathogen makes contact with its host, its goal is simple: to infect.
DynaVox, the leading provider of speech generating devices and symbol-adapted special education software used to assist individuals in overcoming speech, language and learning challenges, today announced the release of two new additions to the Vmax™ line of communication devices, the Vmax+ High Performance and the Vmax+ Battery Efficiency.
Taiho Pharmaceutical Co., Ltd. announced on May 31 that a global Phase III clinical trial (RECOURSE) for the novel combination antimetabolite TAS-102 will start in June this year.
The anti-cancer medicine venetoclax could improve the current therapy for estrogen receptor-positive breast cancer - the most common form of breast cancer in Australia - according to preclinical studies led by Walter and Eliza Hall Institute researchers.
› Verified 5 days ago
Ms. Jennifer Renee Pease Moreno, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: Jhu 600 N Wolfe St, Dept Anesthesia Critical Care Medicine- Blalock 14th Fl, Baltimore, MD 21287 Phone: 410-955-4552 | |
Kristen Marll, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2401 W Belvedere Ave, Baltimore, MD 21215 Phone: 410-601-5209 | |
Mrs. Victoria Volta Manger, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 900 S Caton Ave, Baltimore, MD 21229 Phone: 667-234-3045 | |
Duncan Mcelfresh, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 2401 W Belvedere Ave, Anesthesia Department, Baltimore, MD 21215 Phone: 410-601-5209 Fax: 410-601-9744 | |
Mr. Michael W Hoban, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 301 Saint Paul St, Baltimore, MD 21202 Phone: 410-332-9375 | |
Mrs. Dama Reter Yekeson-koffa, RN, SRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 4940 Eastern Ave, Anesthesia Department Bayview Medical Center, Baltimore, MD 21224 Phone: 443-694-8960 Fax: 410-356-5821 | |
Kelly Mccarthy, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-328-8667 |